Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CAD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    244 result(s) found for: CAD. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-002563-10 Sponsor Protocol Number: BAY86-4875/15961 Start Date*: 2013-06-06
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known ...
    Medical condition: Subjects with known or suspected Coronary Artery Disease (CAD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002261-36 Sponsor Protocol Number: CardioPET™P-02 Start Date*: 2012-11-08
    Sponsor Name:FluoroPharma Medical
    Full Title: A Phase II Open-Labeled Study to Evaluate CardioPET™ as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects with Coronary Artery Disease
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001430-40 Sponsor Protocol Number: 012-06 Start Date*: 2007-05-04
    Sponsor Name:University Hospital Department of Cardiology
    Full Title: Tiral of Invasive versus Medical therapy of Early coronary artery disease in Diabetes (TIME-DM)
    Medical condition: The prevalence of type II diabetes is increasing rapidly, contributing importantly to a new "epidemic" of coronary artery disease (CAD). Atherosclerosis accounts for 65-80% of all death among diabe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001582-25 Sponsor Protocol Number: D7550C00003 Start Date*: 2017-09-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 in patients with coronary artery ...
    Medical condition: Coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-005854-90 Sponsor Protocol Number: ANX005-CAD-01 Start Date*: 2021-02-11
    Sponsor Name:Annexon, Inc.
    Full Title: A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary...
    Medical condition: Primary Cold Agglutinin Disease (CAD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006295-17 Sponsor Protocol Number: MedTrace-002 Start Date*: 2022-04-08
    Sponsor Name:MedTrace Pharma
    Full Title: A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Con...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10006896 CAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003160-27 Sponsor Protocol Number: Sobi.PEGCET-101 Start Date*: 2022-05-31
    Sponsor Name:Swedish Orphan Biovitrum AB
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)
    Medical condition: Patients with Cold Agglutinin Disease (CAD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NO (Prematurely Ended) HU (Prematurely Ended) AT (Completed) IT (Prematurely Ended) BG (Completed) ES (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024044-15 Sponsor Protocol Number: BMS747158-301 Start Date*: 2011-06-08
    Sponsor Name:Lantheus Medical Imaging, Inc.
    Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know...
    Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002678-29 Sponsor Protocol Number: BMS747158-302 Start Date*: 2013-02-21
    Sponsor Name:Lantheus Medical Imaging, Inc.
    Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know...
    Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003200-23 Sponsor Protocol Number: 2013DR3084 Start Date*: 2016-04-21
    Sponsor Name:University Hospital Basel; Neurology
    Full Title: Biomarkers and antithrombotic treatment in cervical artery dissection (TREAT-CAD)
    Medical condition: cervical artery dissection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002055-28 Sponsor Protocol Number: SK-DMDPA-02 Start Date*: 2017-10-13
    Sponsor Name:Synektik Spółka Akcyjna
    Full Title: Safety and dose optimization for [11C] DMDPA as a PET imaging agent for evaluation of myocardial perfusion in subjects with known or suspected coronary artery disease (CAD).
    Medical condition: known or suspected coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003492-39 Sponsor Protocol Number: BR1-125 Start Date*: 2008-04-29
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: A phase III study to compare SonoVue® enhanced myocardial echocardiography (MCE) to single photon emission computerized tomography (ECG-GATED SPECT), at rest and at peak of low-dose Dipyridamole s...
    Medical condition: Suspected coronary artery disease (CAD) indicated for stress ECG-gated SPECT and coronary angiography to clarify whether they have a clinical significant coronary stenosis (=70%).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) GR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017725-19 Sponsor Protocol Number: NC22703 Start Date*: Information not available in EudraCT
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase IIIB multicenter, double-blind, randomized, placebocontrolled study, evaluating the effect of treatment with dalcetrapib 600 mg on Atherosclerotic Disease as measured by I. Coronary Intrava...
    Medical condition: A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011078 Coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001225-11 Sponsor Protocol Number: T58/2013 Start Date*: 2013-08-09
    Sponsor Name:Turku University Hospital
    Full Title: Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease
    Medical condition: Coronary artery desease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003332-36 Sponsor Protocol Number: ID-076A201 Start Date*: 2017-12-20
    Sponsor Name:Idorsia Pharmaceuticals Ltd.
    Full Title: A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adu...
    Medical condition: stable coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) SE (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2023-000135-76 Sponsor Protocol Number: ACE-01-22 Start Date*: 2023-05-15
    Sponsor Name:Adamed Pharma S.A.
    Full Title: Therapeutic Equivalence Study of Twice Daily Acetylsalicylic Acid Tablets 50 mg Compared to Once Daily Acetylsalicylic Acid Tablets 100 mg in Adult Patients Coronary Artery Disease (CAD) or Symptom...
    Medical condition: Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) or after Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    21.1 10047065 - Vascular disorders 10067825 Peripheral arterial disease LLT
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001962-25 Sponsor Protocol Number: BR1-142 Start Date*: 2016-03-04
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis ...
    Medical condition: Suspected or known Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10011082 Coronary artery disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005011-14 Sponsor Protocol Number: GE-265-303 Start Date*: 2018-09-03
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (F 18) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coro...
    Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) imaging of Flurpiridaz (F 18) Injection in patients with suspected coronary artery disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10028603 Myocardial perfusion scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Ongoing) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004064-29 Sponsor Protocol Number: CS747S-B-U4003 Start Date*: 2012-06-11
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A PHARMACODYNAMIC EVALUATION OF SWITCHING FROM TICAGRELOR TO PRASUGREL IN SUBJECTS WITH STABLE CORONARY ARTERY DISEASE: 2ND SWITCHING ANTIPLATELET AGENTS (SWAP 2)
    Medical condition: Stable Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10013098 Disease coronary artery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001713-28 Sponsor Protocol Number: BR1-141 Start Date*: 2016-01-29
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosi...
    Medical condition: Suspected or known Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011082 Coronary artery disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 17:49:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA